کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1930294 | 1050501 | 2011 | 5 صفحه PDF | دانلود رایگان |
Familial hypercholesterolemia (FH) is an autosomal codominant disease characterized by high concentrations of proatherogenic lipoproteins secondary to deficiency in low-density lipoprotein (LDL) receptor. We reported recently the use of in situ stem cell therapy of human adipose tissue-derived multilineage progenitor cells (hADMPCs) in lowering serum total cholesterol in the homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits, an animal model of homozygous FH. Here we demonstrate that pravastatin, an HMG-CoA reductase inhibitor, augmented the cholesterol-lowering effect of transplanted hADMPCs and enhanced LDL clearance in homozygous WHHL rabbit. The results suggest the potential beneficial effects of in situ stem cell therapy in concert with appropriately selected pharmaceutical agents, in regenerative medicine.
► Pravastatin reduced serum total cholesterol in hADMPC-transplanted WHHL rabbits.
► Pravastatin increased the 24 h-LDL-clearance in the hADMPC-transplanted WHHL rabbits.
► In situ stem cell therapy in concert with drug will be potentially beneficial.
Journal: Biochemical and Biophysical Research Communications - Volume 412, Issue 1, 19 August 2011, Pages 50–54